United States
Every company in the roster headquartered in United States.
Every company in the roster headquartered in United States.
441 of 441 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Longeveron (NASDAQ: LGVN)LGVN · Nasdaq | 1 asset: 1 Ph 2 | LaromestrocelPhase 2 · Alzheimer's DiseaseWeak signal | None on record | $60M | $7.3MSep 2026 | ~1.6 qtrs | $12M |
Cognition TherapeuticsCGTX · Nasdaq | 1 asset: 1 Ph 2 | ZervimesinePhase 2 · Alzheimer's DiseaseWeak signal | 31 May 2027Zervimesine · Phase 2 | $57M | $31MSep 2026 | ~8.2 qtrs | $27M |
Corbus PharmaceuticalsCRBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | Sutantatug envedotinPhase 3 · Cervical Cancer | 16 Jan 2027Sutantatug envedotin · Phase 1/2 | $57M | $115MSep 2026 | ~5.0 qtrs | $104M |
Oncolytics Biotech Inc.ONCY · Nasdaq | 1 asset: 1 Ph 2 | PelareorepPhase 2 · Advanced Metastatic Colorectal Cancer | 30 Jul 2027Pelareorep · Phase 1/2 | $56M | $2.4MSep 2026 | Ended Oct 2026 | ~$19M |
Tonix PharmaceuticalsTNXP · Nasdaq | 5 assets: 3 approved, 2 Ph 2 | TNX-1300Phase 2 · Cocaine Intoxication | Feb 2028cyclobenzaprine · Phase 2 | $55M | $163MSep 2026 | ~3.9 qtrs | $80M |
Veru Inc.VERU · Nasdaq | 1 asset: 1 Ph 2 | enobosarmPhase 2 · ObesityPartial signal | Oct 2027enobosarm · Phase 2 | $53M | $24MJun 2026 | ~3.1 qtrs | $16M |
| 2 assets: 1 Ph 2, 1 Ph 1 | WTX-330Phase 1/2 · Advanced Solid Tumors and Non-Hodgkin Lymphoma | None on record | $50M | $42MSep 2026 | ~7.0 qtrs | $23M | |
Gain Therapeutics, Inc.GANX · Nasdaq | 1 asset: 1 Ph 2 | GT-02287Phase 2 · Parkinson's Disease | 30 Jun 2028GT-02287 · Phase 2 | $49M | $12MSep 2026 | ~2.7 qtrs | $8.7M |
Clene NanomedicineCLNN · Nasdaq | 1 asset: 1 Ph 3 | CNM-Au8Phase 2/3 · Multiple SclerosisPartial signal | None on record | $48M | $10.0MSep 2026 | ~2.4 qtrs | $14M |
Apollomics Inc.APLM · Nasdaq | 1 asset: 1 Ph 3 | VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026Vebreltinib · Phase 1/2 | $48M | $3.3MDec 2025 | ~4.1 qtrswith a later raise | $5.5M |
MiNK Therapeutics, Inc.INKT · Nasdaq | 1 asset: 1 Ph 2 | agenT-797Phase 2 · Gastric CancerWeak signal | Jun 2027agenT-797 · Phase 2 | $45M | $7.5MSep 2026 | ~4.2 qtrs | $6.4M |
| 1 asset: 1 Ph 1 | PLN-101095Phase 1 · Non-Small Cell Lung Cancer | Jun 2030PLN-101095 · Phase 1 | $41M | $143MSep 2026 | ~8.5 qtrs | $64M | |
Aldeyra TherapeuticsALDX · Nasdaq | 1 asset: 1 Ph 3 | reproxalapPhase 3 · Dry Eye DiseasePartial signal | None on record | $41M | $41MSep 2026 | ~8.6 qtrs | $12M |
Biomea FusionBMEA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | IcovamenibPhase 2 · Type 2 DiabetesPartial signal | Mar 2027Icovamenib · Phase 2 | $39M | $27MSep 2026 | ~2.4 qtrs | $35M |
Skye BioscienceSKYE · Nasdaq | 1 asset: 1 Ph 2 | nimacimabPhase 2 · Obesity | None on record | $36M | $4.8MSep 2026 | ~0.6 qtrs | $25M |
Grace TherapeuticsGRCE · Nasdaq | 1 asset: 1 Ph 3 | Nimodipine (GTx-104)Phase 3 · Subarachnoid Hemorrhage | None on record | $36M | $21MSep 2026 | ~8.2 qtrs | ~$2.6M |
Annovis Bio (NYSE American: ANVS)ANVS · NYSE American | 1 asset: 1 Ph 3 | BuntanetapPhase 3 · Alzheimer's DiseasePartial signal | Dec 2027Buntanetap · Phase 3 | $36M | $2.8MSep 2026 | Ended Oct 2026 | $53M |
Serina TherapeuticsSER · NYSE American | 1 asset: 1 Ph 1 | SER-252 (PEOZ-apomorphine)Phase 1 · Parkinson's Disease | 31 Jan 2027SER-252 (PEOZ-apomorphine) · Phase 1 | $34M | $19MSep 2026 | ~3.4 qtrs | $15M |
Actinium PharmaceuticalsATNM · | 2 assets: 1 Ph 3, 1 Ph 2 | 131I-apamistamabPhase 3 · Acute Myeloid LeukemiaPartial signal | Feb 2029131I-apamistamab · Phase 2/3 | $34M | $37MJun 2026 | ~6.5 qtrs | $18M |
INmune BioINMB · Nasdaq | 1 asset: 1 Ph 2 | PegipanerminPhase 2 · Alzheimer's DiseasePartial signal | None on record | $32M | $16MSep 2026 | ~5.1 qtrs | $17M |
NextCure, Inc.NXTC · | 3 assets: 1 Ph 2, 2 Ph 1 | NC410Phase 1/2 · Colorectal Cancer | Dec 2027LNCB74 · Phase 1 | $32M | $8.7MSep 2026 | ~0.8 qtrs | $26M |
Pelthos Therapeutics Inc.PTHS · NYSE American | 1 asset: 1 approved | Approved assets only | None on record | $27M | $18MSep 2026 | ~2.2 qtrs | $2.2M |
Rockwell MedicalRMTI · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $25M | $23MSep 2026 | Cash-flow positive | $0.1M |
ABVC BioPharmaABVC · Nasdaq | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 | $24M | $0.1MSep 2026 | Ended Oct 2026 | $0.1M |
CervoMed Inc.CRVO · Nasdaq | 1 asset: 1 Ph 2 | neflamapimodPhase 2 · Dementia with Lewy BodiesPartial signal | None on record | $22M | $20MSep 2026 | ~2.9 qtrs | $19M |
Palatin TechnologiesPTN · NYSE | 3 assets: 1 Ph 3, 2 Ph 2 | PL9643Phase 3 · Dry Eye DiseasePartial signal | None on record | $20M | $7.5MJun 2026 | ~2.2 qtrs | $12M |
BeyondSpring PharmaceuticalsBYSI · Nasdaq | 1 asset: 1 Ph 3 | PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Jun 2029Plinabulin · Phase 3 | $19M | $6.5MJun 2026 | Ended Nov 2026 | $4.6M |
ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq | 1 asset: 1 Ph 2 | (Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026(Z)-endoxifen · Phase 2 | $18M | $21MSep 2026 | ~2.3 qtrs | $19M |
Lipocine Inc.LPCN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $17M | $21MSep 2026 | ~8.6 qtrs | $9.5M |
| 2 assets: 2 Ph 1 | NeldaleucelPhase 1 · Relapsed/Refractory Non-Hodgkin Lymphoma | 28 Feb 2028Neldaleucel · Phase 1 | $16M | $12MJun 2026 | ~4.9 qtrs | $8.8M | |
Cellectar Biosciences, Inc.CLRB · Nasdaq | 1 asset: 1 Ph 3 | Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal | 30 Jun 2027Iopofosine I-131 · Phase 1 | $15M | $25MSep 2026 | ~4.0 qtrs | $16M |
Seres TherapeuticsMCRB · Nasdaq | 1 asset: 1 Ph 1 | SER-155Phase 1 · Bacterial Infections in Allogeneic Stem Cell Transplant | None on record | $15M | $21MSep 2026 | ~1.3 qtrs | $40M |
Allarity Therapeutics, Inc.ALLR · Nasdaq | 1 asset: 1 Ph 2 | stenoparibPhase 2 · Ovarian Cancer | Mar 2027stenoparib · Phase 2 | $14M | — | ~7.9 qtrsJun 2026 | $8.5M |
Matinas BioPharmaMTNB · Nasdaq | 1 asset: 1 Ph 3 | Amphotericin B (MAT2203)Phase 3 · Cryptococcal Meningitis | None on record | $13M | $0.8MJun 2026 | Ended Aug 2026 | $0.1M |
BioCardiaBCDA · Nasdaq | 1 asset: 1 Ph 3 | CardiAMPPhase 3 · Heart FailurePartial signal | 1 Apr 2027CardiAMP · Phase na | $12M | $2.2MSep 2026 | ~1.2 qtrs | $4.5M |
Lisata TherapeuticsLSTA · Nasdaq | 2 assets: 2 Ph 2 | MAR001Phase 2 · HypertriglyceridemiaWeak signal | Nov 2027MAR001 · Phase 2 | $11M | $283MSep 2026 | 10+ years | $8.1M |
Ainos, Inc.AIMD · Nasdaq | 1 asset: 1 other | Interferon alfa (Veldona)Oral Warts in HIV Patients | None on record | $8.9M | $1.4MJun 2026 | Ended Oct 2026 | $7.7M |
VistaGen TherapeuticsVTGN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | fasedienolPhase 3 · Social Anxiety DisorderPartial signal | None on record | $8.9M | $20MSep 2026 | ~1.4 qtrs | ~$48M |
Kyntra BioKYNB · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Oct 2027Roxadustat · Phase 3 | $7.9M | $91MJun 2026 | ~9.6 qtrs | $23M |
MoleculinMBRX · Nasdaq | 1 asset: 1 Ph 3 | AnnamycinPhase 2/3 · Acute Myeloid Leukemia | Aug 2029Annamycin · Phase 2/3 | $7.2M | $7.3MSep 2026 | ~1.1 qtrs | $20M |
MetaViaMTVA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | VanoglipelPhase 2 · MASH / NASHWeak signal | None on record | $7.1M | $8.8MSep 2026 | ~2.1 qtrs | $19M |
BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq | 1 asset: 1 Ph 3 | BezisterimPhase 3 · Alzheimer's DiseasePartial signal | None on record | $7.1M | $7.7MSep 2026 | ~1.7 qtrs | ~$14M |
Exicure, Inc.XCUR · Nasdaq | 1 asset: 1 Ph 2 | Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signal | None on record | $6.8M | $1.7MJun 2026 | Ended Oct 2026 | $2.0M |
Tempest TherapeuticsTPST · Nasdaq | 1 asset: 1 Ph 3 | AmezalpatPhase 3 · Hepatocellular Carcinoma | Dec 2028Amezalpat · Phase 3 | $6.2M | $0.9MSep 2026 | Ended Oct 2026 | $2.7M |
SoligenixSNGX · Nasdaq | 1 asset: 1 Ph 3 | Synthetic hypericinPhase 3Reliable signal | None on record | $5.9M | $9.0MSep 2026 | ~4.7 qtrs | $5.1M |
Kiora Pharmaceuticals, Inc.KPRX · Nasdaq | 1 asset: 1 Ph 2 | KIO-301Phase 2 · Retinitis Pigmentosa | Aug 2027KIO-301 · Phase 2 | $5.2M | $16MSep 2026 | ~8.4 qtrs | $9.1M |
Alzamend NeuroALZN · Nasdaq | 1 asset: 1 Ph 2 | Lithium salicylate/L-proline (AL001)Phase 1/2 · Alzheimer's DiseaseWeak signal | Jul 2027Lithium salicylate/L-proline (AL001) · Phase 1/2 | $5.0M | $7.6MJul 2026 | ~4.7 qtrs | ~$4.3M |
PulmatrixPULM · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | Itraconazole (PUR1900)Phase 2 · Allergic Bronchopulmonary Aspergillosis | None on record | $4.9M | $2.2MJun 2026 | ~2.2 qtrs | <$0.1M |
Processa Pharmaceuticals, Inc.PCSA · Nasdaq | 1 asset: 1 Ph 2 | PCS499Phase 2 · Necrobiosis Lipoidica | None on record | $4.8M | $180MSep 2026 | 10+ years | $6.4M |
Lantern Pharma Inc.LTRN · | 2 assets: 2 Ph 2 | DimesnaPhase 2 · Non-Small Cell Lung CancerPartial signal | Dec 2026Dimesna · Phase 2 | $4.7M | $7.4MJun 2026 | ~3.1 qtrswith a later raise | $8.7M |
Alaunos Therapeutics, Inc.TCRT · Nasdaq | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | None on record | $4.4M | $0.1MJun 2026 | Ended Jul 2026 | $1.6M |
GRI Bio, Inc.GRI · Nasdaq | 1 asset: 1 other | GRI-0803Systemic Lupus Erythematosus | None on record | $2.8M | $9.5MSep 2026 | ~4.0 qtrs | $2.5M |
Senti BiosciencesSNTI · | 2 assets: 2 Ph 1 | SENTI-202Phase 1 · Acute Myeloid Leukemia | None on record | $2.7M | $7.9MJun 2026 | Ended Sep 2026 | $31M |
Jaguar HealthJAGX · Nasdaq | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 | $1.7M | $6.6MJun 2026 | ~3.9 qtrs | $25M |
CurisCRIS · | 1 asset: 1 Ph 2 | EmavusertibPhase 2 · Acute Myeloid Leukemia | Jul 2027Emavusertib · Phase 1/2 | $1.5M | $5.6MSep 2026 | ~0.7 qtrs | $25M |
Genprex, Inc.GNPX · Nasdaq | 1 asset: 1 Ph 2 | Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Quaratusugene Ozeplasmid · Phase 1/2 | $1.4M | $15MSep 2026 | ~4.0 qtrs | $10M |
Aptevo TherapeuticsAPVO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | ALG.APV-527Phase 1/2 · Solid Tumors | Oct 2027Mipletamig · Phase 1 | $0.8M | $9.8MJun 2026 | ~1.6 qtrs | $15M |
Aktis Oncology, Inc.AKTS · | 2 assets: 2 Ph 1 | AKY-1189Phase 1 · Non-Small Cell Lung Cancer | Dec 2027AKY-2519 · Phase 1 | — | $494MSep 2026 | ~23.0 qtrs | ~$94M |
Aligos TherapeuticsALGS · Nasdaq | 1 asset: 1 Ph 2 | ALG-055009Phase 2 · MASH / NASH | None on record | — | $32MSep 2026 | ~1.9 qtrs | $83M |
Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq | 4 assets: 4 approved | Approved assets only | None on record | — | $231MSep 2026 | Cash-flow positive | $92M |
ANI Pharmaceuticals, Inc.ANIP · Nasdaq | 4 assets: 4 approved | Approved assets only | 18 Dec 2029Anastrozole · Phase 3 | — | $421MSep 2026 | Cash-flow positive | $51M |
Bio-Path Holdings, Inc.BPTH · OTC | 2 assets: 1 Ph 2, 1 Ph 1 | PrexigebersenPhase 2 · Acute Myeloid LeukemiaWeak signal | Mar 2027BP1002 · Phase 1 | —no price since 18 Aug 2026 | <$0.1MMar 2026 | Ended Apr 2026 | $8.1M |
BioAtla, Inc.BCAB · OTC | 3 assets: 3 Ph 2 | Ozuriftamab vedotinPhase 2 · Head and Neck Squamous Cell CarcinomaPartial signal | None on record | —no price since 28 Aug 2026 | $1.5MJun 2026 | Ended Jul 2026 | $25M |
| 1 asset: 1 Ph 2 | SilevertinibPhase 1/2 · Non-Small Cell Lung Cancer | Mar 2028Silevertinib · Phase 1/2 | — | $103MSep 2026 | ~12.3 qtrs | $28M | |
Bright Minds Biosciences Inc.DRUG · Nasdaq | 1 asset: 1 Ph 2 | BMB-101Phase 2 · Epilepsy | Nov 2026BMB-101 · Phase 2 | — | $4.2MSep 2024 | ~12.4 qtrs | $0.9M |
Catalyst Pharmaceuticals, Inc.CPRX · Nasdaq | 1 asset: 1 approved | Approved assets only | 6 Apr 2027Perampanel · Phase 2 | —no price since 14 Jul 2026 | — | — | — |
CERo Therapeutics Holdings, Inc.CERO · OTC | 1 asset: 1 Ph 1 | CER-1236Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026CER-1236 · Phase 1 | —no price since 18 Aug 2026 | $0.7MSep 2026 | Ended Oct 2026 | $7.3M |
Connect BiopharmaCNTB · Nasdaq | 1 asset: 1 Ph 3 | RademikibartPhase 3 · Atopic DermatitisPartial signal | 31 Dec 2026Rademikibart · Phase 3 | — | $31MJun 2026 | ~2.1 qtrs | $54M |
CytoDynCYDY · OTCQB | 1 asset: 1 Ph 3 | LeronlimabPhase 2/3 · HIVPartial signal | Jan 2028Leronlimab · Phase 2 | —no price since 18 Aug 2026 | $16MAug 2026 | ~3.3 qtrs | $7.2M |
Emmaus Life SciencesEMMA · OTCQB | 1 asset: 1 approved | Approved assets only | None on record | — | $2.8MJun 2026 | Cash-flow positive | $0.2M |
Enanta Pharmaceuticals, Inc.ENTA · Nasdaq | 2 assets: 2 Ph 2 | EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signal | Dec 2026zelicapavir · Phase 2 | — | $190MJun 2026 | ~18.8 qtrs | $93M |
| 1 asset: 1 Ph 2 | CR-001Phase 1/2 · Solid Tumors | Feb 2029CR-001 · Phase 1/2 | — | $289MSep 2026 | ~14.1 qtrs | $177M | |
Immuneering CorporationIMRX · Nasdaq | 1 asset: 1 Ph 3 | AtebimetinibPhase 3 · Pancreatic Cancer | Jun 2027Atebimetinib · Phase 1/2 | — | $145MSep 2026 | ~9.4 qtrs | $55M |
Indivior Pharmaceuticals, Inc.INDV · Nasdaq | 3 assets: 3 approved | Approved assets only | None on record | —no price since 2 Nov 2026 | $305MSep 2026 | Cash-flow positive | $54M |
Inmagene BiopharmaceuticalsIMA · Nasdaq | 1 asset: 1 Ph 2 | OlevaprubartPhase 2 · Atopic DermatitisWeak signal | Dec 2027Olevaprubart · Phase 2 | — | $127MSep 2026 | ~13.9 qtrs | $29M |
Karyopharm TherapeuticsKPTI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | EltanexorPhase 1/2 · Multiple MyelomaWeak signal | Dec 2026Selinexor · Phase 2/3 | —no price since 10 Nov 2026 | $65MJun 2026 | ~4.0 qtrs | $121M |
Krystal Biotech, Inc.KRYS · | 4 assets: 1 approved, 1 Ph 2, 2 Ph 1 | KB707Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026KB407 · Phase 1 | — | $912MSep 2026 | Cash-flow positive | $60M |
MeiraGTx LimitedMGTX · Nasdaq | 1 asset: 1 Ph 2 | AAV-GAD gene therapyPhase 2 · Parkinson's DiseaseWeak signal | Oct 2029AAV-GAD gene therapy · Phase 1/2 | — | $187MSep 2026 | Cash-flow positive | $160M |
NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028Troculeucel · Phase 1/2 | —no price since 18 Aug 2026 | <$0.1MMar 2025 | Ended Mar 2025 | $9.3M |
Obsidian Therapeutics, Inc.OBX · Nasdaq | 1 asset: 1 Ph 2 | OBX-115Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2029OBX-115 · Phase 1/2 | — | $216MSep 2026 | ~11.2 qtrs | $89M |
OrganonOGN · NYSE | 12 assets: 11 approved, 1 other | Atozet (ezetimibe/atorvastatin)Atherosclerotic Cardiovascular Disease | Aug 2027Tapinarof · Phase 3 | — | $1.5BSep 2026 | Cash-flow positive | $357M |
| 1 asset: 1 other | LinebackerSolid Tumors | None on record | —no price since 18 Aug 2026 | <$0.1MJun 2026 | Ended Jul 2026 | $0.1M | |
Provectus PharmaceuticalsPVCT · OTC | 2 assets: 1 Ph 3, 1 Ph 2 | rose bengal disodiumPhase 3 · Locally Advanced Cutaneous Melanoma | None on record | —no price since 18 Aug 2026 | — | ~1.9 qtrsJun 2026 | $1.0M |
PureTech HealthPTCHF · OTC | 2 assets: 2 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 | —no price since 18 Aug 2026 | $281MDec 2024 | ~8.4 qtrs | $69M |
Quince TherapeuticsQNCX · Nasdaq | 1 asset: 1 Ph 2 | LAM-001Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | None on record | —no price since 9 Oct 2026 | $105MSep 2026 | ~8.6 qtrs | $31M |
REGENXBIO Inc.RGNX · Nasdaq | 3 assets: 3 Ph 3 | Surabgene lomparvovecPhase 3 · Age-Related Macular DegenerationWeak signal | Dec 2026Surabgene lomparvovec · Phase 2/3 | — | $251MSep 2026 | ~6.6 qtrs | $234M |
Sagimet Biosciences Inc.SGMT · Nasdaq | 1 asset: 1 Ph 3 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Aug 2027Denifanstat · Phase 3 | — | $236MSep 2026 | ~31.5 qtrswith a later raise | $42M |
Sangamo TherapeuticsSGMOQ · OTC | 1 asset: 1 Ph 2 | TX200Phase 1/2 · Kidney Transplant Rejection Prophylaxis | None on record | —no price since 18 Aug 2026 | $28MMar 2026 | Ended Jul 2026 | $113M |
Summit TherapeuticsSMMT · Nasdaq | 1 asset: 1 Ph 3 | IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2026Ivonescimab · Phase 3 | — | $630MSep 2026 | ~4.8 qtrs | $80M |
TG THERAPEUTICS, INC.TGTX · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | — | $505MSep 2026 | Cash-flow positive | $236M |
TScan Therapeutics, Inc.TCRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | TSC-101Phase 3 · Hematologic Malignancies | Jun 2029TSC-101 · Phase 3 | — | $78MSep 2026 | ~2.8 qtrs | $91M |
Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseaseWeak signal | 31 Dec 2028Pepinemab · Phase 1/2 | —no price since 18 Aug 2026 | $1.1MDec 2024 | Ended Jan 2025 | $13M |
Windtree TherapeuticsWINT · OTC | 1 asset: 1 Ph 2 | rostafuroxinPhase 2 · Resistant Hypertension with Adducin/Ouabain Polymorphisms | None on record | —no price since 14 Aug 2026 | $0.2MSep 2025 | Ended Oct 2025 | $8.6M |
XBiotechXBIT · Nasdaq | 2 assets: 2 Ph 2 | NatrunixPhase 2 · Rheumatoid ArthritisPartial signal | 15 Jan 2027Natrunix · Phase 2 | — | $105MSep 2026 | ~10.3 qtrs | $47M |
7 Hills Pharma, LLCPrivate | 1 asset: 1 Ph 2 | AlintegimodPhase 1/2 · Non-Small Cell Lung Cancer | 31 Dec 2027Alintegimod · Phase 1/2 | — | — | — | — |
A2 Biotherapeutics Inc.Private | 4 assets: 4 Ph 2 | A2B395Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026A2B530 · Phase 1/2 | — | — | — | — |
Aardvark TherapeuticsPrivate | 1 asset: 1 Ph 3 | ARD-101Phase 3 · Prader-Willi SyndromePartial signal | None on record | — | — | — | — |
AbcentraPrivate | 1 asset: 1 Ph 2 | OrticumabPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | 8 Feb 2027Orticumab · Phase 2 | — | — | — | — |
Aclipse TherapeuticsPrivate | 1 asset: 1 Ph 3 | LobeglitazonePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
ADARx PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | ADX-850Phase 1 · Hypertension | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.